A preemptive strike against HIV

Willyard, Cassandra
February 2009
Nature Medicine;Feb2009, Vol. 15 Issue 2, p126
Academic Journal
This article describes the research being done to determine if the drugs tenofovir and Truvada will prevent people from contracting HIV when taken on a daily basis. The strategy, called pre-exposure prophylaxis (PrEP), has the advantage of being discrete compared to the use of condoms. Researchers plan to enroll up to 18,000 people in more than 10 countries for the clinical trials and hope to have results in 2009.


Related Articles

  • Editorial [Hot Topic:Antibody Neutralization (Guest Editor: Kelly Stefano Cole)]. Cole, Kelly Stefano; Ross, Ted M. // Current HIV Research;Nov2007, Vol. 5 Issue 6, p505 

    Each year, more than 5 million individuals are newly infected with HIV-1 [1]. To address this, the development of an HIV/AIDS vaccine has remained one of the highest priorities in biomedical research for the last 25 years. During this time, we have witnessed some success with the development of...

  • Relative frequency of infections among hospitalized injecting drug user-HIV positive patients in Razi hospital, Ahvaz, SW Iran (2001-2003). Alavi, Seyed Mohammad // Jundishapur Journal of Microbiology;2008, Vol. 1 Issue 1, p6 

    Frequency of infections in Injecting Drug Users (IDU) varies in different areas according to socioeconomic and geographic situation as well as Human Immunodeficiency Virus (HIV) infection rate. The present study was performed to determine the frequency of infections in IDU-HIV positive patients....

  • Preexisting Resistance to Nonnucleoside Reverse-Transcriptase Inhibitors Predicts Virologic Failure of an Efavirenz-Based Regimen in Treatment-Naive HIV-1-Infected Subjects. Kuritzkes, Daniel R.; Lalama, Christina M.; Ribaudo, Heather J.; Marcial, Michelle; Meyer III, William A.; Shikuma, Cecilia; Johnson, Victoria A.; Fiscus, Susan A.; D'Aquila, Richard T.; Schackman, Bruce R.; Acosta, Edward P.; Gulick, Roy M. // Journal of Infectious Diseases;3/15/2008, Vol. 197 Issue 6, p867 

    A case-cohort study was used to determine the effect of baseline nonnucleoside reverse-transcriptase inhibitor (NNRTI) resistance, as assessed by viral genotyping, on the response to efavirenz-containing regimens in AIDS Clinical Trials Group A5095. The sample included a random cohort of...

  • HIV prevention and harm reduction programmes in the Russian Federation: the Renewal project in the Republic of Tatarstan.  // European Health Report 2005;2005, p28 

    The article highlights the success story of the Renewal project in the Republic of Tatarstan in Russia, one of the HIV prevention and harm reduction programs in the Russian Federation. The project started small in 1999 in Tatarstan with external financial support, and developed into a...

  • Measuring HIV-1-Specific T Cell Immunity: How Valid Are Current Assays? Patricia D'Souza, M.; Altfeld, Marcus // Journal of Infectious Diseases;2/1/2008, Vol. 197 Issue 3, p337 

    The authors reflect on the validity of the current assays of HIV-1-Specific T Cell Immunity vaccines. The author believes that the development of an effective HIV-1 vaccine to prevent virus transmission or stop the progression of the disease is a major challenge in biomedical research. They also...

  • The HIV/AIDS Epidemic.  // Population Reports;Apr99, Vol. 27 Issue 1, p6 

    States that the extent of the AIDS epidemic underscores the urgent need for condoms. How HIV affects the human body; How HIV/AIDS spreads; Prospects for AIDS in sub-Saharan Africa and developing countries of Asia.

  • HIV: A step ahead of drug resistance. Rowan, Alison // Nature Reviews Microbiology;Apr2005, Vol. 3 Issue 4, p273 

    The article reports on the result of a study conducted by Doctor I. Hauber and colleagues that identifies a new physiological target to be considered in developing antiretroviral agents. Researchers noted that blocking a host-cell factor called human deoxyhypusine synthase (DHS) can be an...

  • WHO releases new HIV recommendations.  // PharmacoEconomics & Outcomes News;12/12/2009, Issue 593, p1 

    The article focuses on the guidelines issued by the World Health Organization (WHO) for the treatment and prevention of human immunodeficiency virus (HIV). WHO recommends the use of antiretroviral therapy (ART) from week 14 of pregnancy until the end of breastfeeding. It also suggests the use of...

  • New HIV Drugs. Karlin, Susan // Discover;Jan2007, Vol. 28 Issue 1, p43 

    The article states that medical researchers are developing new categories of anti-HIV drugs. Entry inhibitor drugs stop the virus from entering healthy cells by binding to receptors on the cells' surfaces. Integrase inhibitors prevent viral DNA from incorporating itself into the human cell's...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics